New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls. Read the Q3 2026 report

Scribe Therapeutics Inc.

SCTX

Healthcare Biotechnology

Scribe Therapeutics Inc.’s revenue for fiscal 2025 (year ended December 2025) was $51.2 million.

12.07 1.15 −8.70%

After hours trading: 12.00, down 0.58%, last trade Fri 7:39pm Eastern.

Market cap
$250.4M
P/E
n/m
Fwd P/E FY26e
n/m
Dividend yield
—
F-score
n/a
ROIC
—
Net debt / EBITDA
—
Payout ratio
—

An Income Statement, also known as a Profit and Loss Statement, summarizes a company's revenues, expenses, and profits over a specific period. It highlights how revenue is transformed into net income, showcasing operational efficiency. Key components include total revenue, cost of goods sold (COGS), gross profit, operating expenses, and net profit. Businesses use the Income Statement to assess financial performance, make strategic decisions, and ensure profitability. Investors and stakeholders analyze it to gauge the company’s financial health and future growth potential.

Dec '25
Revenue
51.17
Gross Profit
51.17
Operating Income
51.17
EBT
51.17
Income after Tax
51.17
Net Income Common
(21.81)
EPS (Basic)
(8.98)
EPS (Diluted)
(8.98)
Shares (Basic, Weighted)
2.43
Shares (Diluted, Weighted)
2.43
Gross Margin
100.00%
EBIT Margin
100.00%
EBT margin
100.00%
Net Profit Margin
(42.62%)
EBITDA
51.17
EBIT
51.17
Income from Continuous Operations
(21.81)
Income from Discontinued Operations
0.00
Consolidated Net Income/Loss
(21.81)
EPS (Basic, from Continuous Ops)
(8.98)
EPS (Basic, Consolidated)
(8.98)
EPS (Diluted, from Cont. Ops)
(8.98)
Shares (Diluted, Average)
2.43
EPS (Diluted, Consolidated)
(8.98)
EBITDA Margin
100.00%

Fold the line items

In millions of $ except per-share values · columns are period end dates · fundamentals updated Nov 18, 2026